SCHEMBL2685052

SCHEMBL2685052

Cn1cc(-c2ccc3c(c2)N(C(=O)[C@H](Cc2ccccc2)NC(=O)O)CC3)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 2/20 0.49
CTSV O60911 2/20 0.49
CTSL P07711 2/20 0.49
CTSS P25774 2/20 0.49
CTSB P07858 1/20 0.49
FPR2 P25090 3/20 0.47
HDAC8 Q9BY41 2/20 0.46
GPR142 Q7Z601 1/20 0.43
CREBBP Q92793 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TRIM24 O15164 1/20 0.42
WNT1 P04628 2/20 0.42
GSK3B P49841 2/20 0.42
DYRK1A Q13627 2/20 0.42
CTSK P43235 1/20 0.41
FPR1 P21462 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3793422 1.00 EP300 (0.49) EP300CTSVCTSLCTSSCTSB
SCHEMBL5960866 0.89 SCN9A (0.48) EP300CTSVCTSLCTSSCTSB
SCHEMBL2685377 0.86 FPR2 (0.49) CTSLCTSSFPR2HDAC8GAA
SCHEMBL5960867 0.86 EP300 (0.49) EP300HDAC8CREBBPRAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL2685119 0.85 EP300 (0.49) EP300HDAC8CREBBPRAB9ASMN1; SMN2
SCHEMBL2687136 0.85 FPR2 (0.50) CTSVCTSLCTSSFPR2GPR142
SCHEMBL2685129 0.84 FPR2 (0.54) FPR2GAAMAPTNPSR1FPR1
SCHEMBL2684655 0.79 FPR2 (0.65) FPR2SMN1; SMN2GAAMAPTNPSR1
SCHEMBL2686135 0.76 SCN9A (0.47) CTSLCTSSCTSBFPR2GAA
SCHEMBL2686138 0.76 SCN9A (0.47) CTSLCTSSCTSBFPR2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A EP300 261/4885CTSV 3613/4885CTSL 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.